Half a century of L-DOPA

Current Topics in Medicinal Chemistry

Volumn 9, Issue 10, 2009, Pages 880-893

  Mena, María Ángeles ^a   Casarejos, Maria José ^a   Solano, Rosa María ^a   García De Yébenes, Justo ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Apoptosis; Dopamine neurons; Glial cells; Glutathione; L DOPA responsive dystonia; MAP kinase; Parkin gene; Parkinson's disease

Indexed keywords

CARBOXYLYASE; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; LEVODOPA; NERVE GROWTH FACTOR; NEUROTRANSMITTER; SELEGILINE; TOCOPHEROL;

ARTICLE; CATECHOLAMINE METABOLISM; CELL CULTURE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG RELEASE; HUMAN; LIFESPAN; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; NEURONS; PARKINSON DISEASE;

EID: 74249083172     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789378263     Document Type: Article

References (88)

1. Carlsson, A.; Lindqvist, M.; Magnusson, T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180, 1200.
2. Guggenheim, M. Dioxiphenylalanin: Eine neue Amimosäure aus Vitia Faba. Z. Physiol. Chem. 1913, 88, 276-284.
3. Kempster, P. The miracle of L-DOPA. In: Essays for Andrew. A festschrift for Adrew John Lees. Butter, J.O.J. Eds.; Remous Ltd: Dorset, UK, 1938, pp. 59-75.
4. Holtz, P.; Heise, R.; Lüdtke, K. Fermentativer Abbau von LDioxyphenylalanin (Dopa) durch Niere. Naunyn-Schmiedeberg's Arch. Exp. Pathol. Pharmak. 1938, 191, 87-118.
5. Carlsson, A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 1959, 11, 490-493.
6. Carlsson, A.; Lindqvist, M.; Magnusson, T.; Waldeck, B. On the presence of 3-hydroxytyramine in brain. Science 1958, 127, 471.
7. Ehringer, H.; Hornykiewicz, O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. 1960, 38, 1236-1239.
8. Birkmayer, W.; Hornykiewicz, O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin. Wochenschr. 1961, 73, 787-788.
9. Fehling, C. Treatment of Parkinson's syndrome with L-dopa. A double blind study. Acta Neurol. Scand. 1966, 42, 367-372.
10. McGeer, P.L.; Zeldowicz, L.R. Administration of dihydroxyphenylalanine to Parkinsonian patients. Can. Med. Assoc. J. 1964, 90, 463-466.
11. Barbeau, A.; Sourkes, T.L.; Murphy, G.F. Les catecholamines de la maladie de Parkinson. In: Monoamines et Système Nerveux Central. Ajuriaguerra, J. Eds.; Georg et Cie: Geneva, 1962, 247-267.
12. Cotzias, G.C.; Van Woert, M.H.; Schiffer, L.M. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 1967, 276, 374-379.
13. Cotzias, G.C.; Papavasiliou, P.S.; Gellene, R. Modification of Parkinsonism - chronic treatment with L-dopa. N. Engl. J. Med. 1969, 280, 337-345.
14. Koller, W.C.; Hubble, J.P. Levodopa therapy in Parkinson's disease. Neurology 1990, 40, (10 Suppl 3), 40-7, discussion 47-49.
15. Hutton, J.T.; Morris, J.L. Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease. Neurology 1992, 42, 51-56; discussion 57-60.
16. LeWitt, P.A. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa. Neurology 1992, 42, 29-32; discussion 57-60.
17. Antonini, A.; Isaias, I.U.; Canesi, M.; Zibetti, M.; Mancini, F.; Manfredi, L.; Dal Fante, M.; Lopiano, L.; Pezzoli, G. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov. Disord. 2007, 22, 1145-1149.
18. Biskup, S.; Gerlach, M.; Kupsch, A.; Reichmann, H.; Riederer, P.; Vieregge, P.; Wullner, U.; Gasser, T. Genes associated with Parkinson syndrome. J. Neurol. 2008, 255 (Suppl. 5), 8-17.
19. Lesage, S.; Brice, A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 2009, 18, 48-59.
20. Nygaard, T.G.; Trugman, J.M.; de Yebenes, J.G.; Fahn, S. Doparesponsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 1990, 40, 66-69.
21. Tanaka, H.; Endo, K.; Tsuji, S.; Nygaard, T.G.; Weeks, D.E.; Nomura, Y.; Segawa, M. The gene for hereditary progressive dystonia with marked diurnal fluctuation maps to chromosome 14q. Ann. Neurol. 1995, 37, 405-408.
22. De Lonlay, P.; Nassogne, M.C.; van Gennip, A.H.; van Cruchten, A.C.; Billatte de Villemeur, T.; Cretz, M.; Stoll, C.; Launay, J.M.; Steenberger-Spante, G.C.; van den Heuvel, L.P.; Wevers, R.A.; Saudubray, J.M.; Abeling, N.G. Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation. J. Inherit. Metab. Dis. 2000, 23, 819-825.
23. Ichinose, H.; Suzuki, T.; Inagaki, H.; Ohye, T.; Nagatsu, T. Molecular genetics of dopa-responsive dystonia. Biol. Chem. 1999, 380, 1355-1364.
24. De La Fuente-Fernandez, R.; Furtado, S.; Guttman, M.; Furukawa, Y.; Lee, C.S.; Calne, D.B.; Ruth, T.J.; Stoessl, A.J. VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. Synapse 2003, 49, 20-28.
25. de la Fuente-Fernandez, R.; Schulzer, M.; Mak, E.; Calne, D.B.; Stoessl, A.J. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004, 127, 888-899.
26. Nagatsu, T.; Levitt, M.; Udenfriend, S. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis. J. Biol. Chem. 1964, 239, 2910-2917.
27. Garcia de Yébenes, J.; Gervas, J.J.; Muradas, V.; Bazán, E. Aspectos farmacocinéticos y farmacodinámicos de las enfermedad de Parkinson. In: Centenario de la Neurología en España. Hospital de la Santa Creu y Sant Pau, Eds.; Barcelona, 1983, pp. 181-190.
28. Neira, W.D.; Sanchez, V.; Mena, M.A.; de Yebenes, J.G. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov. Disord. 1995, 10, 66-70.
29. Gervas, J.J.; Muradas, V.; Bazan, E.; Aguado, E.G.; de Yebenes, J.G. Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 1983, 33, 278-282.
30. Mena, M.A.; Pardo, B.; Casarejos, M.J.; Fahn, S.; Garcia de Yebenes, J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov. Disord. 1992, 7, 23-31.
31. Mena, M.A.; Pardo, B.; Paino, C.L.; De Yebenes, J.G. Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. Neuroreport 1993, 4, 438-440.
32. Mytilineou, C.; Han, S.K.; Cohen, G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J. Neurochem. 1993, 61, 1470-1478.
33. Pardo, B.; Mena, M.A.; Fahn, S.; Garcia de Yebenes, J. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov. Disord. 1993, 8, 278-284.
34. Pardo, B.; Mena, M.A.; Casarejos, M.J.; Paino, C.L.; De Yebenes, J.G. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 1995, 682, 133-143.
35. Pardo, B.; Mena, M.A.; de Yebenes, J.G. L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J. Neurochem. 1995, 64, 576-582.
36. Hefti, F.; Melamed, E.; Bhawan, J.; Wurtman, R.J. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology 1981, 31, 1194-1195.
37. Fahn, S. Welcome news about levodopa, but uncertainty remains. Ann. Neurol. 1998, 43, 551-554.
38. Murer, M.G.; Dziewczapolski, G.; Menalled, L.B.; Garcia, M.C.; Agid, Y.; Gershanik, O.; Raisman-Vozari, R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann. Neurol. 1998, 43, 561-575.
39. Mena, M.A.; Casarejos, M.J.; Carazo, A.; Paino, C.L.; Garcia de Yebenes, J. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 1996, 7, 441-445.
40. Mena, M.A.; Casarejos, M.J.; Carazo, A.; Paino, C.L.; Garcia de Yebenes, J. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J. Neural. Transm. 1997, 104, 317-328.
41. Mena, M.A.; Casarejos, M.J.; Alcazar, A.; Herranz, A.; Paino, C.L.; De Yebenes, G.J. The critical factor for L-DOPA toxicity on DA neurons is glia. In: Understanding Glia Cells; Castellano, B.; Gonzalez, B.; Nieto-Sampedro, M. Eds.; Kluwer Academic Publishers: Boston, 1998, pp. 213-232.
42. Mena, M.A.; Davila, V.; Sulzer, D. Neurotrophic effects of LDOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J. Neurochem. 1997, 69, 1398-1408.
43. Mena, M.A.; Khan, U.; Togasaki, D.M.; Sulzer, D.; Epstein, C.J.; Przedborski, S. Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J. Neurochem. 1997, 69, 21-33.
44. Mena, M.A.; Davila, V.; Bogaluvsky, J.; Sulzer, D. A synergistic neurotrophic response to l-dihydroxyphenylalanine and nerve growth factor. Mol. Pharmacol. 1998, 54, 678-686.
45. Rodriguez-Martin, E.; Canals, S.; Casarejos, M.J.; de Bernardo, S.; Handler, A.; Mena, M.A. L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells. J. Neurochem. 2001, 78, 535-545.
46. Mena, M.A.; de Bernardo, S.; Casarejos, M.J.; Canals, S.; Rodriguez-Martin, E. The role of astroglia on the survival of dopamine neurons. Mol. Neurobiol. 2002, 25, 245-263.
47. de Bernardo, S.; Canals, S.; Casarejos, M.J.; Rodriguez-Martin, E.; Mena, M.A. Glia-conditioned medium induces de novo synthesis of tyrosine hydroxylase and increases dopamine cell survival by differential signaling pathways. J. Neurosci. Res. 2003, 73, 818-830.
48. Mena, M.A.; Casarejos, M.J.; de Yébenes, J.G. Neurotoxic and Neurotrophic effects of L-DOPA on dopamine neurons. Recent Res. Dev. Neurochem. 1999, 2, 91-97.
49. Mena, M.A.; de Yebenes, J.G. Drug-induced parkinsonism. Expert Opin. Drug. Saf. 2006, 5, 759-771.
50. Przedborski, S.; Jackson-Lewis, V.; Muthane, U.; Jiang, H.; Ferreira, M.; Naini, A.B.; Fahn, S. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 1993, 34, 715-723.
51. Cohen, G.; Spina, M.B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 1989, 26, 689-690.
52. Tatton, W.G.; Ansari, K.; Ju, W.; Salo, P.T.; Yu, P.H. Selegiline induces "trophic-like" rescue of dying neurons without MAO inhibition. Adv. Exp. Med. Biol. 1995, 363, 15-16.
53. Maruyama, W.; Akao, Y.; Carrillo, M.C.; Kitani, K.; Youdium, M.B.; Naoi, M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 2002, 24, 675-682.
54. De Marchi, U.; Pietrangeli, P.; Marcocci, L.; Mondovi, B.; Toninello, A. L-Deprenyl as an inhibitor of menadione-induced permeability transition in liver mitochondria. Biochem. Pharmacol. 2003, 66, 1749-1754.
55. Graham, D.G.; Tiffany, S.M.; Bell, W.R., Jr.; Gutknecht, W.F. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 1978, 14, 644-653.
56. Mytilineou, C.; Danias, P. 6-Hydroxydopamine toxicity to dopamine neurons in culture: potentiation by the addition of superoxide dismutase and N-acetylcysteine. Biochem. Pharmacol. 1989, 38, 1872-1875.
57. Rice, M.E. Ascorbate regulation and its neuroprotective role in the brain. Trends. Neurosci. 2000, 23, 209-216.
58. Kalir, H.H.; Mytilineou, C. Ascorbic acid in mesencephalic cultures: effects on dopaminergic neuron development. J. Neurochem. 1991, 57, 458-464.
59. Nistico, G.; Ciriolo, M.R.; Fiskin, K.; Iannone, M.; De Martino, A.; Rotilio, G. NGF restores decrease in catalase activity and increases superoxide dismutase and glutathione peroxidase activity in the brain of aged rats. Free Radic. Biol. Med. 1992, 12, 177-181.
60. De Vitry, F.; Hillion, J.; Catelon, J.; Thibault, J.; Benoliel, J.J.; Hamon, M. Dopamine increases the expression of tyrosine hydroxylase and aromatic amino acid decarboxylase in primary cultures of fetal neurons. Brain Res. Dev. Brain. Res. 1991, 59, 123-131.
61. Leslie, F.M. Neurotransmitters as neurotrophic factors. In: Neurotrophic factors. Fallon, J.H.; Loughlin, S.E. Eds.; Academic Press: San Diego, 1993, pp. 565-598.
62. Rosenberg, P.A.; Loring, R.; Xie, Y.; Zaleskas, V.; Aizenman, E. 2,4,5-trihydroxyphenylalanine in solution forms a non-N-methyl-D-aspartate glutamatergic agonist and neurotoxin. Proc. Natl. Acad. Sci. USA 1991, 88, 4865-4869.
63. Mena, M.A.; Garcia de Yebenes, J. Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia. Neuroscientist 2008, 14, 544-560.
64. Solano, R.M.; Casarejos, M.J.; Menendez-Cuervo, J.; Rodriguez-Navarro, J.A.; Garcia de Yebenes, J.; Mena, M.A. Glial dysfunction in parkin null mice: effects of aging. J. Neurosci. 2008, 28, 598-611.
65. Werner, P.; Cohen, G. Glutathione disulfide (GSSG) as a marker of oxidative injury to brain mitochondria. Ann. N. Y. Acad. Sci. 1993, 679, 364-369.
66. Damier, P.; Hirsch, E.C.; Zhang, P.; Agid, Y.; Javoy-Agid, F. Glutathione peroxidase, glial cells and Parkinson's disease. Neurosci. 1993, 52, 1-6.
67. Raps, S.P.; Lai, J.C.; Hertz, L.; Cooper, A.J. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 1989, 493, 398-401.
68. Sagara, J.I.; Miura, K.; Bannai, S. Maintenance of neuronal glutathione by glial cells. J. Neurochem. 1993, 61, 1672-1676.
69. Colton, C.A.; Pagan, F.; Snell, J.; Colton, J.S.; Cummins, A.; Gilbert, D.L. Protection from oxidation enhances the survival of cultured mesencephalic neurons. Exp. Neurol. 1995, 132, 54-61.
70. Han, S.K.; Mytilineou, C.; Cohen, G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J. Neurochem. 1996, 66, 501-510.
71. Yan, C.Y.; Ferrari, G.; Greene, L.A. N-acetylcysteine-promoted survival of PC12 cells is glutathione-independent but transcription-dependent. J. Biol. Chem. 1995, 270, 26827-26832.
72. Ferrari, G.; Yan, C.Y.; Greene, L.A. N-acetylcysteine (D- and Lstereoisomers) prevents apoptotic death of neuronal cells. J. Neurosci. 1995, 15, 2857-2866.
73. Jenner, P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol. Scand. Suppl. 1993, 146, 6-13.
74. Sian, J.; Dexter, D.T.; Lees, A.J.; Daniel, S.; Agid, Y.; Javoy-Agid, F.; Jenner, P.; Marsden, C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 1994, 36, 348-355.
75. Tohgi, H.; Abe, T.; Saheki, M.; Hamato, F.; Sasaki, K.; Takahashi, S. Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment. Neurosci. Lett. 1995, 184, 21-24.
76. Zhou, Q.Y.; Quaife, C.J.; Palmiter, R.D. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 1995, 374, 640-643.
77. Thomas, S.A.; Matsumoto, A.M.; Palmiter, R.D. Noradrenaline is essential for mouse fetal development. Nature 1995, 374, 643-646.
78. Itier, J.M.; Ibanez, P.; Mena, M.A.; Abbas, N.; Cohen-Salmon, C.; Bohme, G.A.; Laville, M.; Pratt, J.; Corti, O.; Pradier, L.; Ret, G.; Joubert, C.; Periquet, M.; Araujo, F.; Negroni, J.; Casarejos, M.J.; Canals, S.; Solano, R.; Serrano, A.; Gallego, E.; Sanchez, M.; Denefle, P.; Benavides, J.; Tremp, G.; Rooney, T.A.; Brice, A.; Garcia de Yebenes, J. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 2003, 12, 2277-2291.
79. Serrano, A.; Menendez, J.; Casarejos, M.J.; Solano, R.M.; Gallego, E.; Sanchez, M.; Mena, M.A.; Garcia de Yebenes, J. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 2005, 49, 208-219.
80. Casarejos, M.J.; Menendez, J.; Solano, R.M.; Rodriguez-Navarro, J.A.; Garcia de Yebenes, J.; Mena, M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem. 2006, 97, 934-946.
81. Solano, R.M.; Menendez, J.; Casarejos, M.J.; Rodriguez-Navarro, J.A.; Garcia de Yebenes, J.; Mena, M.A. Midbrain neuronal cultures from parkin mutant mice are resistant to nitric oxideinduced toxicity. Neuropharmacology 2006, 51, 327-340.
82. Mena, M.A.; Rodriguez-Navarro, J.A.; Ros, R.; de Yebenes, J.G. On the pathogenesis and neuroprotective treatment of Parkinson disease: what have we learned from the genetic forms of this disease? Curr. Med. Chem. 2008, 15, 2305-2320.
83. Casarejos, M.J.; Solano, R.M.; Menendez, J.; Rodriguez-Navarro, J.A.; Correa, C.; Garcia de Yebenes, J.; Mena, M.A. Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. J. Neurochem. 2005, 94, 1005-1014.
84. Jaeger, C.B.; Ruggiero, D.A.; Albert, V.R.; Park, D.H.; Joh, T.H.; Reis, D.J. Aromatic L-amino acid decarboxylase in the rat brain: immunocytochemical localization in neurons of the brain stem. Neurosci. 1984, 11, 691-713.
85. Furukawa, N.; Arai, N.; Goshima, Y.; Miyamae, T.; Ohshima, E.; Suzuki, F.; Fujita, K.; Misu, Y. Endogenously released DOPA is a causal factor for glutamate release and resultant delayed neuronal cell death by transient ischemia in rat striata. J. Neurochem. 2001, 76, 815-824.
86. Misu, Y.; Kitahama, K.; Goshima, Y. L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system. Pharmacol. Ther. 2003, 97, 117-137.
87. Opacka-Juffry, J.; Brooks, D.J. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. Mov. Disord. 1995, 10, 241-249.
88. Mena, M.A.; Casarejos, M.J.; Rodríguez-Martín, E.; Solano, R.M.; Menéndez, J.; García de Yébenes, J. Neuroprotective and neurotoxic effects of L-DOPA in rat midbrain dopaminergic neurons in culture. in: neurobiology of DOPA as a neurotransmitter: Misu, Y.; Goshima, Y.; Eds.; Taylor and Francis Group: New York, 2006, pp. 303-319.